Factors That Affect Survival Outcomes in Patients with Endometrial Clear Cell Carcinoma.

clear cell carcinoma endometrial cancer recurrence survival

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
24 Nov 2022
Historique:
received: 19 09 2022
revised: 13 11 2022
accepted: 21 11 2022
entrez: 11 12 2022
pubmed: 12 12 2022
medline: 12 12 2022
Statut: epublish

Résumé

Background: Clear cell carcinoma (CCC) is a rare aggressive histologic subtype of endometrial cancer with a high relapse rate. In the present study, we sought to evaluate the prognostic factors of disease relapse and overall survival. Methods: We conducted retrospective cohort studies that included endometrial CCC patients treated at our institution. Predictive variables of survival outcomes were evaluated considering factors that determine the survival of patients with endometrioid carcinoma. Results: Fifty-five patients with a median age of 68 years and a median follow-up period of 31 months were included in the present study. Recurrence-free and overall survival rates did not differ among patients with early-stage and advanced-stage disease (RFS HR 1.51 (95% CI 0.63, 3.61), OS HR 1.36 (0.56, 3.31)). Patients with upper abdominal metastases had significantly shorter progression-free and overall survival intervals (log-rank < 0.001). The Gehan-Breslow-Wilcoxon analysis indicated worse survival rates for patients with advanced disease (p = 0.040); however, the log-rank test that gave equal weight to all time points did not reveal significant differences (log-rank = 0.576). Conclusion: Clear cell carcinoma is an aggressive histologic subtype of endometrial cancer that seems to be moderately affected by known predictors of survival rates in endometrioid carcinoma patients, except for the disease stage. Further research is needed to evaluate whether the molecular profiling of these patients may help predict survival outcomes.

Identifiants

pubmed: 36498506
pii: jcm11236931
doi: 10.3390/jcm11236931
pmc: PMC9737404
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Clin Oncol. 2013 Jul 10;31(20):2607-18
pubmed: 23733771
Int J Gynecol Cancer. 2017 Oct;27(8):1714-1721
pubmed: 28945214
Gynecol Oncol. 2019 Mar;152(3):599-604
pubmed: 30551884
Lancet Oncol. 2018 Mar;19(3):295-309
pubmed: 29449189
Anticancer Res. 2010 Apr;30(4):1327-34
pubmed: 20530448
Front Endocrinol (Lausanne). 2022 Feb 24;13:762589
pubmed: 35282450
Acta Biomed. 2022 Jan 19;92(6):e2021362
pubmed: 35075084
Front Oncol. 2021 Dec 02;11:732782
pubmed: 34926250
Cancers (Basel). 2021 May 26;13(11):
pubmed: 34073635
Arch Gynecol Obstet. 2016 Mar;293(3):485-92
pubmed: 26626183
Bull Cancer. 2012 Jan;99(1):43-9
pubmed: 22198346
Gynecol Oncol. 2021 Sep;162(3):804-808
pubmed: 34266691
Gynecol Oncol. 2019 Nov;155(2):365-373
pubmed: 31500893
Am J Obstet Gynecol. 2021 Sep;225(3):237.e1-237.e24
pubmed: 33957111
Br J Cancer. 2006 Mar 13;94(5):642-6
pubmed: 16495918
Int J Gynecol Cancer. 2017 Jan;27(1):69-76
pubmed: 27668398
J Natl Compr Canc Netw. 2021 Aug 01;19(8):888-895
pubmed: 34416706
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Gynecol Oncol. 2022 Mar;164(3):658-666
pubmed: 35063279
Gynecol Oncol. 2020 Jul;158(1):3-11
pubmed: 32331700
Gynecol Oncol. 2018 Jan;148(1):147-153
pubmed: 29129389

Auteurs

Vasilios Pergialiotis (V)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Dimitrios Haidopoulos (D)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Theano Christodoulou (T)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Ioannis Rodolakis (I)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Ioannis Prokopakis (I)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Michalis Liontos (M)

First Department of Propedeutic Surgery, National Kapodistrian University of Athens, Hippocration Hospital, 11528 Athens, Greece.

Alexandros Rodolakis (A)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Nikolaos Thomakos (N)

First Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.

Classifications MeSH